ReviewArchives of toxicology2016
Antibiotic resistance mechanisms in M. tuberculosis: an update.
Review in Archives of toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 246 citations in OpenAlex.
- Carbonic Anhydrases in Mycobacteria: Linking Metabolic Adaptation to Phenotypic Drug Tolerance.Current microbiology · 2026Review
- Machine learning-guided discovery of spirocyclic inhibitors targeting Mycobacterium tuberculosis FtsZ.Folia microbiologica · 2026Article
- Mucoadhesive Chitosan-Gellan Gum Nanoparticles for Rifampicin Delivery: Taguchi Optimization and In Vitro Release Behavior.Pharmaceutics · 2026Article
- Uncovering resistance pathways to first- and last-line antibiotics inMicrobial genomics · 2026Article
- The lipid language of tuberculosis:mBio · 2026Review
- Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controlsAntimicrobial agents and chemotherapy · 2026Article
- Discovery of novel InhA inhibitors through structural bioinformatics and machine learning-driven QSAR screening of natural products.Biology methods & protocols · 2026Article
- Structure based discovery of VMP-7 as a promising GlgE targeting lead againstFrontiers in microbiology · 2026Article
- Tanshinones target drug-resistant tuberculosis: efficacy, selectivity, and potential mechanism of action.RSC medicinal chemistry · 2025Article
- Efflux pumps positively contribute to rifampin resistance in rpoB mutant Mycobacterium tuberculosis.Annals of clinical microbiology and antimicrobials · 2025Article
- Investigation of anti-microbial and cytotoxic potential of Streptomyces werraensis GRS9 derived from the sediments of river Ganga.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Exploring the application of herbal photosensitizers in antimicrobial photodynamic therapy against3 Biotech · 2025Review
- Drug-loaded liposomes for macrophage targeting in3 Biotech · 2025Article
- The Exoproteome and Surfaceome of ToxigenicJournal of proteome research · 2025Article
- Challenges of Multidrug-Resistant Tuberculosis Meningitis: Current Treatments and the Role of Glutathione as an Adjunct Therapy.Vaccines · 2024Review
- Structure of a Cyclic Peptide as an Inhibitor ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- Introducing Casbah, Kronus, and MmasiCarm, Members of the Mycobacteriophage Subcluster B3.PHAGE (New Rochelle, N.Y.) · 2024Article
- Telemedicine as a tool to prevent multi-drug resistant tuberculosis in poor resource settings: Lessons from Nigeria.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Synthesis and Characterization of New N-acyl Hydrazone Derivatives of Carprofen as Potential Tuberculostatic Agents.Antibiotics (Basel, Switzerland) · 2024Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Treatment of tuberculosis (TB) has been a therapeutic challenge because of not only the naturally high resistance level of Mycobacterium tuberculosis to antibiotics but also the newly acquired mutations that confer further resistance. Currently standardized regimens require patients to daily ingest up to four drugs under direct observation of a healthcare worker for a period of 6-9 months. Although they are quite effective in treating drug susceptible TB, these lengthy treatments often lead to patient non-adherence, which catalyzes for the emergence of M. tuberculosis strains that are increasingly resistant to the few available anti-TB drugs. The rapid evolution of M. tuberculosis, from mono-drug-resistant to multiple drug-resistant, extensively drug-resistant and most recently totally drug-resistant strains, is threatening to make TB once again an untreatable disease if new therapeutic options do not soon become available. Here, I discuss the molecular mechanisms by which M. tuberculosis confers its profound resistance to antibiotics. This knowledge may help in developing novel strategies for weakening drug resistance, thus enhancing the potency of available antibiotics against both drug susceptible and resistant M. tuberculosis strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.